Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A ?2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

Stock Information for Fortress Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc.

Avenue Therapeutics Announces Reverse Stock Split
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.